Maravai LifeSciences’ stock dipped slightly to $6.23 after reporting Q2 2026 earnings, revealing a net loss of $12.4 million on $51.4 million in revenue—though this marked a significant improvement from the prior year’s losses. Despite a 9% revenue boost, ongoing losses and a large customer concentration raised concerns about the company’s stability. Positive indicators included a better-than-expected gross margin of 58.9% and increased guidance for adjusted EBITDA, driven largely by growth in mRNA and GMP consumables. However, the market remains cautious about the long-term durability of demand amidst potential pressures from competition and client in-house capabilities.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrvi/maravai-lifesciences-holdings/news/maravai-lifesciences-mrvi-stock-faces-losses-despite-margin
